The transcription factor STAT5 (signal transducer and activator of transcription 5) is frequently activated in hematological malignancies and represents an essential signaling node downstream of the BCR-ABL oncogene. STAT5 can be phosphorylated at three positions, on a tyrosine and on the two serines S725 and S779. We have investigated the importance of STAT5 serine phosphorylation for BCR-ABL-induced leukemogenesis. In cultured bone marrow cells, expression of a STAT5 mutant lacking the S725 and S779 phosphorylation sites (STAT5 SASA ) prohibits transformation and induces apoptosis. Accordingly, STAT5
INTRODUCTION
Janus kinase/signal transducer and activator of transcription (JAK/ STAT) molecules are key players in a number of highly conserved signaling pathways involved in cell-fate decisions such as differentiation, proliferation and apoptosis. 1 Mounting evidence pinpoints a role for JAK/STAT signaling in human cancer and STAT proteins are attracting increasing interest as potential molecular targets for cancer therapy. 2 Constitutively active forms of JAK2 have been identified as drivers of myeloid and T lymphoid leukemia. [3] [4] [5] Studies in STAT5a/b-deficient mice have revealed that STAT5a/b are essential effectors for JAK2-triggered leukemogenesis. 6, 7 In other malignancies, STAT5 signaling is activated downstream of oncogenic tyrosine kinases and contributes to transformation and tumor maintenance. An example of a tyrosine kinase that exerts its oncogenic function via STAT5 is the Abelson (BCR-ABL) oncogene, generated by a reciprocal translocation t (9;22) and found in leukemic cells of human chronic myeloid leukemia and acute lymphoid leukemia patients. 8, 9 Fusion with the BCR protein turns the Abelson kinase into a constitutively active tyrosine kinase capable of transforming hematopoietic cells. Deletion of STAT5 during induction or maintenance of BCR-ABL þ leukemia leads to abrogation of the disease. 10, 11 STAT proteins are phosphorylated on tyrosine and serine residues and phosphorylation is generally necessary for full transcriptional activity, although there is mounting evidence that unphosphorylated STAT1 activates a certain subset of target genes. 12 Tyrosine phosphorylation allows dimerization of STAT molecules that is believed to be a prerequisite for nuclear translocation. 13 The importance of phosphorylated STAT5 for hematopoietic malignancies is underlined by observations in lymphoid, myeloid and erythroid leukemias that have constitutive STAT5 Y694 phosphorylation. 14, 15 The introduction of constitutively active STAT5a mutants into murine hematopoietic cells suffices to induce multilineage leukemia in mice. 16 Although the role of serine phosphorylation in transcriptional control has been intensively investigated, only limited information is available about its importance in STAT5a/b function. [17] [18] [19] [20] Serine phosphorylation of STAT1 is required for cytotoxic T-cell responses and/or interferon-g-mediated innate immunity. 21, 22 Phosphorylation of STAT3 on S727 is needed for Ras-mediated tumor formation. 23 Consistently, serine phosphorylation of STAT3 has been linked to the growth of solid tumors such as prostate or skin cancer. 24, 25 Moreover, STAT3 and STAT1 are constitutively phosphorylated on serine residues in a subset of acute myeloid leukemia 26 as well as B-cell chronic lymphocytic leukemia, although the significance of the modification is still unclear.
The causal link between serine phosphorylation of STAT5a and leukemogenesis has only recently been established. 27 Using bone marrow (BM) transplantations, we described a critical role for STAT5a serine phosphorylation in STAT5a-driven leukemogenesis (using a constitutively active murine STAT5a as driver oncogene). 27 The importance of this result was underlined by the finding that both serine residues of STAT5a (S726 and S780, corresponding to murine S725 and S779) are phosphorylated in human myeloid malignancies including acute myeloid leukemia and BCR-ABL p210 þ chronic myeloid leukemia. 27 This study provided the first indication 1 Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria; that serine phosphorylation of STAT5a might play a part in myeloid leukemia driven by constitutively active STAT5a, indirectly implying that serine phosphorylation of STAT5a might be required in other naturally occurring malignancies that depend on STAT5. We thus investigated whether STAT5 serine phosphorylation is downstream of oncogenic tyrosine kinases, using BCR-ABL-induced disease as a model system. We report here that serine phosphorylation of STAT5a is necessary for nuclear localization of STAT5 in BCR-ABL þ cells. We identify group I p21-activated kinases (PAKs) as upstream regulators and suggest that they might represent an attractive therapeutic point of attack independent of BCR-ABL kinase activity. 
MATERIALS AND METHODS

Mouse strains
Site-directed mutagenesis
Site-directed mutagenesis was performed using the QuikChange sitedirected Mutagenesis Kit from Stratagene (La Jolla, CA, USA) according to the manufacturer's instructions (using pMSCV-STAT5a-IRES-GFP as parental vector).
Generation of leukemic cell lines and in vitro deletion of endogenous STAT5
The following leukemic cell lines were used: murine BCR- Mx-1Cre cross were transformed and maintained in RPMI supplemented with 10% fetal calf serum, 50 mM 2-mercaptoethanol and 100 U/ml penicillin, 100 mg/ml streptomycin (PAA, Pasching, Austria) as previously described. 30 For Stat5 deletion, stable Stat5 fl/fl
Mx-1Cre BCR-ABL p185 þ cell lines were incubated for 48 h in 1000 U/ml recombinant interferon-b (PBL Interferon Source, Piscataway, NJ, USA). After 2 weeks, deletion efficiency was verified by genotyping PCR as described before.
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Transfection of leukemic cell lines Mx-1Cre BCR-ABL p185 þ cell lines were transduced with pMSCV-IRES-GFP-based constructs encoding individual STAT5 variants by co-culture with gp þ E86 ecotropic retroviral producer cells as described previously. 31 Vector-positive (GFP þ ) cells were sorted using a fluorescence-activated cell sorting (FACS) Aria III device (BD Biosciences, San Jose, CA, USA).
Transplantation studies in mice
A total of 2500 BCR-ABL p185 þ cells were injected via the tail vein into nonirradiated NSG mice. Mice were monitored daily. Sick mice were killed and analyzed for spleen weight, white blood cell count and the presence of STAT5-vector-positive leukemic cells (GFP þ ) in BM, spleen and peripheral blood (PB) by flow cytometry. Differential hemograms were assessed using a VetABC Blood Counter (Scil Animal Care, Viernheim, Germany). The Hemacolor staining kit (Merck Millipore, Billerica, MA, USA) was used for hematoxylin and eosin staining.
Flow cytometry and cell sorting of leukemic cells A total of 5 Â 10 5 cells were stained and analyzed by a FACS Canto II flow cytometer equipped with 488, 633 and 405 nm lasers using the FACS Diva software (Becton-Dickinson, Franklin Lakes, NJ, USA) as described before.
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High-purity FACS sorting was performed on a FACS Aria III equipped with a 488 nm laser at 4 1C (Becton-Dickinson).
Transfection and immunofluorescence staining of HEK cells HEK 293T cells were transfected with a pcDNA 3.1.-based vector expressing BCR-ABL p185 using PolyFect (Qiagen, Hilden, Germany). Cells were cultured with Dulbecco's modified Eagle's medium (PAA) high glucose supplemented with 10% fetal calf serum (PAA), 50 mM 2-mercaptoethanol (SigmaAldrich, St. Louis, MO, USA), 100 U/ml penicillin, 100 mg/ml streptomycin (PAA) and 1000 mg/ml G418 (InvivoGen, San Diego, CA, USA) to select for stable BCR-ABL p185 -expressing cells. The localization of yellow fluorescent protein (YFP)-tagged STAT5 protein was examined by immunofluorescent laser scanning microscopy (Olympus IX71, 20-fold magnification) using a 530/550 nm filter (U-MNG2 filter, Olympus, Tokyo, Japan).
Cell extracts and immunoblotting
Whole-cell extracts and cellular fractionations were performed as previously described. 10, 32 For immunoblotting, proteins (50-100 mg) were separated on a 7% SDS polyacrylamide gel and transferred to nitrocellulose membranes. Membranes were probed with antibodies from Santa Cruz (Dallas, TX, USA) against STAT5a/b (N-20; C-17), a-tubulin (DM1A), b-actin (C-15), HSC70 (B-6) and pERK Y204 (E-4). Lamin-B (ab45848-100) was purchased from Abcam (Cambridge, UK Data were normalized to internal controls by linear regression to the mean of the 32 dimethyl sulfoxide wells (set to 100% of control) and the mean of the 32 positive control wells (set to 0% of control) using Pipeline Pilot (Accelrys, San Diego, CA, USA). Screening data were visualized with Spotfire (Spotfire Inc., Cambridge, MA, USA) software. Screening was performed in duplicate.
The methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay was conducted in 96-well plates with 20 000 cells per well in 100 ml medium. Kinase inhibitors (Kinase Inhibitor Toolbox, Tocris) were added at 10 mM concentration followed by 24 h of incubation. Positive and negative controls were included as above. Cells were incubated for 3 h with 10 ml MTT (5 mg/ml MTT; Sigma-Aldrich). Upon addition of 100 ml acidified isopropanol (4 mM HCl, 0.1% Nonidet P-40; Sigma-Aldrich), absorbance was measured at 590 nm on an EnSpire multimode plate reader (Perkin Elmer).
Kinase inhibitor studies K562, KU812, BCR-ABL p185 þ and v-ABL p160 þ leukemic cell lines were seeded in a six-well dish at a concentration of 10 6 cells per ml. Kinase inhibitors were added and after incubation at 37 1C and 5% CO 2 , cells were harvested, washed twice with ice-cold phosphate-buffered saline and subjected to immediate lysis as described previously. 33 The following inhibitors were purchased from Calbiochem (Billerica, MA, USA): KN-93, H-89, PD98059, TDZD-8, roscovitine and olomoucine. PIM1 kinase inhibitor, STAT5 serine phosphorylation in leukemia A Berger et al BIO and IPA-3 were purchased from Tocris. Flavopiridol, CAL-101 and foretinib were purchased from Selleck Chemicals (Houston, TX, USA). Anisomycin was purchased from Sigma-Aldrich; olomoucine II from Alexis Biochemical (San Diego, CA, USA) and SB 203580 from Jena-Bioscience (Jena, Germany). All inhibitors were dissolved in dimethyl sulfoxide. As negative control 0.1% dimethyl sulfoxide was used.
Immunoprecipitation studies STAT5-or PAK1-specific antibodies were incubated with lysates for 1.5 h at room temperature, and then for 1 h with magnetic beads conjugated to proteins A and G (Bio-Adembeads PAG, Ademtech, Pessac, France). Beads were pelleted with a magnet and washed 3 times. Protein complexes were eluted by incubation with PAG elution buffer (Ademtech) and analyzed by immunoblotting.
In vitro kinase assays
Recombinant mouse TAT-STAT5a and TAT-STAT5b were produced and purified as described previously. 34 Recombinant mouse PAK1 and Cdc42/ PAK1 were purchased from SignalChem (Richmond, BC, Canada) and recombinant Rac1 from Cytoskeleton (Denver, CO, USA). Recombinant TAT-STAT5 proteins (20 ng) were incubated with PAK1 kinase (100 ng) in buffer containing 25 mM Tris-HCl (pH 7.5), 5 mM b-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na 3 VO 4 , 10 mM MgCl 2 , 2 mM MnCl 2 and 100 mM ATP for 30 min at 37 1C. Kinase reactions were stopped by adding Laemmli buffer and STAT5 phosphorylation was detected by immunoblotting with an anti-pSTAT5 S779 antibody (Affinity Bioreagents, Golden, CO, USA).
H thymidine incorporation assays
A total of 50 000 cells per well were seeded in 96-well plates, inhibitors were added and cells were pulsed with 1 mCi of 3 H thymidine (Perkin Elmer) per well. Cells were harvested 18 h later using a Filtermate Harvester (Perkin Elmer).
3 H thymidine uptake was determined using a Top Count 4.00 Scintillation Counter (Perkin Elmer). All experiments were performed in triplicate.
shRNA knockdown experiments For short hairpin RNA (shRNA)-mediated knockdown of PAK2 in murine BCR-ABL p185 þ cells, TRC clone TRCN0000025213 (Open Biosystems, Huntsville, AL, USA) was used and a nonsilencing shRNA (RHS4080) served as control. Lentivirus production and infection were performed as previously described. 12 
Statistical analysis
Analysis was performed by means of an unpaired t-test or a one-way analysis of variance followed by Tukey's test. Data are presented as averages±s.d. and were analyzed by GraphPad (GraphPad Software, San Diego, CA, USA). Differences in Kaplan-Meier plots were assessed for statistical significance using the logrank test.
RESULTS
Expression of STAT5
SASA hampers leukemic cell viability in vitro
To test the role of STAT5 serine phosphorylation in cellular transformation, we infected murine wild-type (wt) fetal liver cells with v-ABL p160 þ in combination with STAT5 wt , STAT5 SASA or an empty vector control (pMSCV-IRES-GFP). The STAT5 SASA construct contains two serine sites mutated to alanine: STAT5 S725A and STAT5 S779A (a diagram of the STAT5 mutants is provided in Supplementary Figure 1 The cells were transplanted into nonirradiated NSG mice (scheme in Figure 2a ). We observed a significant increase in disease latency upon transplantation of STAT5 SASA -expressing leukemic cells compared with the cohort that had received STAT5 wt cells (Figure 2a) . In a subsequent experiment, all animals were killed on day 18 (scheme in Figure 2b ). We noticed a significant attenuation of the severity of the disease upon transplantation of STAT5 SASA leukemic cells as shown by significantly reduced spleen weight ( Figure 2c ) and white blood cell count (Figure 2d ). Blood smears revealed lower numbers of tumor cells in the PB (Figure 2e ). Histological spleen sections substantiated these findings and showed less infiltration of leukemic cells (Figure 2f ). Differences in disease severity were also obvious when we monitored leukemic cells in PB (Figure 2g ) and spleens (Figure 2h ) by FACS analysis. Although we observed no differences in leukemic infiltration in the BM on day 18 (12.4±8.2 vs 12.3±5.3 for the STAT5 wt and STAT5 SASA groups, P ¼ nonsignificant, data not shown), there were profound differences in the PB and in the spleen. In summary, the leukemic cell load was significantly reduced upon transplantation of BCR-ABL p185 þ STAT5 SASA cells. (Figure 4e ).
Group I PAK kinases as upstream regulators of STAT5 S779 in BCR-ABL p185 þ cells Blocking STAT5 S779 phosphorylation and thereby nuclear translocation of STAT5 might represent a way to inhibit the transcriptional activity of STAT5, which is essential for maintenance of BCR-ABLdriven disease. To identify the kinase(s) upstream of STAT5 S779 we performed in silico screens employing group-based phosphorylation scoring, KinasePhos, NetPhosK, prediction of protein kinase-specific phosphorylation site, PredPhospho, Scansite and PhosphoMotif finder. Results for potential candidates are summarized in Figure 5a . As both murine STAT5 S779 and human STAT5 S780 are flanked by prolines, we focused on hits that represent proline-directed serine/threonine kinases. Mitogenactivated protein kinases (MAPKs) and cyclin-dependent kinases (CDKs) were consistently identified. Protein kinases A, B and C (PKA, PKB and PKC), glycogen synthase kinase-3b, Ca 2 þ /calmodulin-dependent protein kinases, PAKs and mammalian target of Figure 5a summarizes two individual rounds of experiments. The target profiles of hit compounds were largely consistent with the in silico predictions. In a next step, we used western blot analysis for validation and found that two independently acting group I PAK kinase inhibitors (IPA-3 and PF-3758309) suppress STAT5 S779 phosphorylation in both human and murine BCR-ABL þ cells (Figures 5b and c) . CDK inhibitors were also analyzed in more depth as CDK8 has previously been defined as upstream kinase for STAT proteins. 12, 35 We treated BCR-ABL p185 þ cells with CDK inhibitors including flavopiridol and analyzed levels of pSTAT5 S779 by immunoblotting. As depicted in Figure 5c and Supplementary Figure 2 , we failed to detect any reduction of pSTAT5 S779 upon inhibition of CDKs. Similarly, inhibitors of MAPK, PKA, PKB, PKC, Ca 2 þ /calmodulindependent protein kinases, mammalian target of rapamycin, glycogen synthase kinase-3b and PIM1-that were predicted as potential upstream kinases-failed to exert any effect ( Supplementary Figures 3 and 4) .
These data lead to a testable prediction: if PAK kinases phosphorylate STAT5
S779 , PAK kinase inhibition should prevent the accumulation of nuclear STAT5. In line with the results in STAT5 S779A mutant cells, we indeed observed a reduction of nuclear STAT5 upon treating murine BCR-ABL p185 þ and KU812 cells with the PAK inhibitor PF-3758309 (Figures 5d and e) . This led us to conclude that group I PAK kinases are direct or indirect upstream regulators of STAT5 S779 phosphorylation, controlling the nuclear localization of STAT5.
PAK kinases directly phosphorylate STAT5 S779 Whereas PAK1 and PAK2 are expressed in human BCR-ABL þ cells, it appears that only PAK2 is found in murine leukemic cells: we failed to detect any PAK1 protein in murine BCR-ABL p185 þ cells (Figure 6a ). Co-immunoprecipitation experiments revealed complexes of STAT5, PAK1, PAK2 and Rac1 in KU812 cells (Figure 6b ). STAT5 was consistently associated with PAK1, PAK2 in K562 (Supplementary Figure 5) and in murine BCR-ABL þ cells (Supplementary Figure 6) . The interaction was specific for STAT5 as no complexes were detectable upon immunoprecipitation of STAT1 in K562 or murine BCR-ABL þ cells (Supplementary Figures  5 and 6 ). Thus, group I PAK kinases directly interact with STAT5.
To investigate whether PAK kinases phosphorylate STAT5, we performed in vitro kinase assays, incubating recombinant PAK1 kinase with recombinant TAT-STAT5a protein. Only in the presence of Rac1-which is required to activate PAK kinases-did phosphorylation of STAT5 S779 become apparent ( Figure 6c ). As negative controls we used recombinant mouse STAT5b protein that is highly homologous to STAT5a as well as a truncated version of STAT5a (STAT5 D749 ) (Supplementary Figure 7a) . Stat5b does not harbor a serine at position 779 but at position 778. However, STAT5b 778 is not flanked by prolines. We failed to detect any signal using these constructs. Identical results were obtained when we used recombinant PAK2 (Supplementary Figure 7b) . The data support the conclusion that group I PAK kinases directly phosphorylate STAT5 S779 . To further substantiate the link between PAK1/2 and STAT5 S779 phosphorylation, we performed knockdown experiments against PAK2 in murine BCR-ABL p185 þ -transformed cells (Supplementary Figures 8a and b) . We focused on PAK2 here as murine BCR-ABL p185 þ cells do not express PAK1 (see Figure 6a ). Despite the successful knockdown of PAK2, the remaining PAK2 proteins displayed increased kinase activity. Accordingly, STAT5 S779 phosphorylation was enhanced indicating a so far unrecognized pronounced feedback loop that was independent of mitogen-activated protein kinase kinase activity as the mitogen-activated protein kinase kinase inhibitor U0126 remained without effect (Supplementary Figure 8c) .
STAT5
S779 phosphorylation is independent of BCR-ABL kinase activity As STAT5
Y694 phosphorylation depends on BCR-ABL kinase activity, we investigated whether phosphorylation of STAT5 Y694 phosphorylation decreased within 15 min and was hardly detectable after 60 min. In contrast, the level of STAT5 S725 and STAT5 S779 phosphorylation remained unaffected for 6 h (Figure 7a ). This indicates that STAT5 serine phosphorylation is independent of BCR-ABL kinase activity and does not require concomitant STAT5 Y694 phosphorylation. We reasoned that-if independent of BCR-ABL kinase activity-activation of PAK kinases should not be impaired by imatinib treatment. We used antibodies that recognize phosphorylated STAT5 S780 , PAK1 and PAK2 (pPAK1 T423 and pPAK2 T402 ), corresponding to the activated forms of the proteins, after incubation of KU812 cells with 2 mM imatinib. As expected, STAT5 Y694 phosphorylation rapidly declined (Figure 7b ). However, there was no change to the levels of activated PAK1 and PAK2 and the extent of STAT5 S780 phosphorylation also remained unaltered upon imatinib treatment, suggesting that STAT5 S780 is phosphorylated independently of BCR-ABL.
Support came from an experiment with cells overexpressing a Tyr-phosphorylation mutant of STAT5 (STAT5 Y694F ), STAT5 SASA or STAT5 wt . STAT5 is phosphorylated on residues S725 and S779 even in the absence of tyrosine phosphorylation (Figure 7c) . We reasoned that BCR-ABL p185 þ cells with reduced PAK protein have an enhanced susceptibility if treated with PAK inhibitors. This was indeed the case; the half-maximal inhibitory concentration (IC 50 ) for PF-3758309 was reduced from 8.79 to 0.63 nM (random vs PAK2 shRNA) whereas the IC 50 for imatinib remained unchanged (Figure 7d) .
In summary, the data indicate that there are two distinct and independent pathways that control the phosphorylation and thus the intracellular localization of STAT5: phosphorylation of STAT5 Y694 controls the protein's dimerization, whereas STAT5 S779 phosphorylation directly regulates its intracellular localization (Figure 7e ). 
DISCUSSION
The JAK/STAT pathway has been shown to be among the most important signaling pathways in the development and maintenance of tumors. 36 Inhibitors of individual JAKs and STATs are currently in development and are thought to hold promise for treating a wide variety of tumors. A number of JAK inhibitors are undergoing clinical trials and first compounds have been approved by the Food and Drug Administration (FDA). 37 Nevertheless, there have not yet been any convincing demonstrations of STAT inhibitors that are both safe and sufficiently specific to be appropriate for use in humans. The critical STAT molecules are STAT3 and STAT5, both of which are constitutively activated in a broad range of solid and hematopoietic tumors. Targeting these molecules directly via their dimerization domains has proven especially difficult. We present a different approach to inhibiting the activity of STAT5 in tumor maintenance, based on blocking an upstream serine kinase and consequently preventing nuclear translocation. It is likely that the mechanism we describe will turn out to be relevant to other types of tumor. Although a number of signaling pathways cooperate to support cell viability, the role of STAT5 in BCR-ABL-induced disease is key. 38, 39 The deletion of STAT5a/b is incompatible with cell survival 10, 11 and STAT5 is essential for initial transformation as well as for leukemia maintenance. Loss of STAT5 signaling causes leukemic cell death even in imatinib-resistant cells. Furthermore, deletion of STAT5 is well tolerated by the adult host organism-at least in the murine system. 10, 11 STAT5 thus fulfills all the criteria of a therapeutic target.
STAT proteins lack a catalytic domain but can be targeted by inhibiting critical post-translational modifications. Most attention has been paid to Y694, the phosphorylation of which permits dimerization and nuclear translocation. In nontransformed cells, JAK kinases are responsible for tyrosine phosphorylation, whereas in BCR-ABL þ cells the fusion kinase itself phosphorylates STAT5 Y694 . 40 Treatment of BCR-ABL þ cells with imatinib or any of the other tyrosine kinase inhibitors abolishes STAT5 Y694 phosphorylation. All BCR-ABL kinase inhibitors thus indirectly target STAT5
Y694 phosphorylation, and hence all of them essentially represent a single therapeutic avenue against STAT5.
STAT5 is additionally phosphorylated on highly conserved serine residues in the transactivation domain. 20 We show here that this phosphorylation is independent of STAT5 Y694 phosphorylation: treatment of BCR-ABL . STAT5a serine phosphorylation has recently been implicated in leukemogenesis. 27 BM transplantation studies using a constitutively active version of STAT5a (cS5a) caused leukemia with STAT5a itself as the driving oncogene but mutation of serine residues (STAT5 S725A and STAT5
S779A
) abrogated disease. This indicated the importance of STAT5 serine phosphorylation but did not address its relevance in forms of leukemia driven by human transforming tyrosine kinases. We provide initial evidence that serine phosphorylation is important for kinase-driven STAT5 hyperactivation. Fetal 44 and mutation of STAT1
L407A hinders importin-a5 binding and thus causes cytoplasmic localization. 45, 46 Similarly, phosphorylation of STAT5 controls the protein's intracellular localization and Src-dependent tyrosine phosphorylation in STAT5 Src homology 2 domain favors the cytoplasmic accumulation of the protein. 47 We propose that STAT5 S779 phosphorylation is critically involved in nuclear translocation. The requirement for STAT5 S779 phosphorylation has previously been overlooked, probably because it has been masked by the presence of endogenous STAT5. 19, 20, 27, 48 phosphorylation and PAK kinases, although in an unexpected manner. Reduced expression of PAK2 in murine BCR-ABL p185 þ cells is associated with an enhanced activity of the remaining protein and paralleled by increased STAT5 S779 phosphorylation. This observation might point at a so far unknown feedback loop that tightly adjusts protein expression and activation status. As PAK kinases regulate mitogen-activated protein kinase kinase 1 activation via phosphorylation on S298, 49 this represents an obvious candidate. However, no effects were observed if we blocked mitogen-activated protein kinase kinase 1 in our cellular system. Nevertheless, reduced PAK protein levels render the cells more susceptible to treatment with PAK inhibitors but not to BCR-ABL tyrosine kinase inhibitors, providing further support for our concept.
Group I PAK kinases 1-3 are known to possess auto-inhibitory phosphotyrosine interaction domains and to require activation by a p21 GTPase, either Rac or Cdc42. 50 There is convincing evidence that Rac GTPases are key regulators of BCR-ABL-induced malignancies, 51, 52 but the underlying mechanism has remained obscure. Our results suggest that the effect is at least partially mediated by inhibition of nuclear accumulation of STAT5. It is currently unknown which signaling pathways activate PAK kinases in nonsolid tumors, although integrin signaling was recently shown to be crucial for acute myeloid leukemia. 53 The constitutive activation of PAK kinases may also result from the accelerated cell cycle progression in leukemic cells: PAK kinases are active when cells initiate mitosis and rapidly dividing cells might not have sufficient time to deactivate them. PAK kinases have been reported to be overexpressed in human cancers and are considered promising therapeutic targets. 54 They have a wide variety of downstream targets, such as c-Raf and MAPK signaling that contribute to a tumorigenic state, and hence the therapeutic potential of inhibiting PAK kinases is considerable. 54 To the best of our knowledge, there have been no previous studies of PAK kinases and STAT5 in transformed cells, although there is a report that PAK1 regulates lobuloalveolar development in a STAT5 S779 -dependent manner. 55 Using BCR-ABL þ disease we now show that PAK kinases act via STAT5 in an oncogenic setting, thereby adding STAT5 to the list of signaling mediators downstream of PAK kinases. STAT5 may be one of the key downstream targets of PAK kinases in certain types of tumors, mediating their protooncogenic effects.
The importance of STAT5 serine phosphorylation for transformation and its independence from the BCR-ABL-STAT5 Y694 axis offers a therapeutic opportunity that is distinct from that afforded by current tyrosine kinase inhibitors. Inhibiting PAK1 and/or PAK2 may prevent nuclear localization of STAT5 and as a consequence its oncogenic activity. Targeting PAK kinases may represent a feasible way to circumvent the difficulties in developing effective direct inhibitors of STAT5 and might provide a promising strategy for treating cancers with hyperactivated STAT5.
